GSK, Moderna and Pfizer are all looking at potential respiratory syncytial virus vaccine sales slumps thanks to recently ...

The whole RSV vaccine field took a beating when the CDC’s immunization committee doled out a limited recommendation last ...

The European Union health regulator on Friday recommended expanded use of GSK's respiratory syncytial virus (RSV) vaccine in ...

British drugmaker GSK cut its forecast for 2024 vaccine sales on Wednesday after quarterly revenue from its blockbuster ...

In the face of broader rollout challenges that could limit uptake of Arexvy, GSK said it is confident that sales for its ...

GSK plc (GSK, GSK.L) announced Monday that its Respiratory Syncytial Virus or RSV vaccine, Arexvy, has received positive opinion from ...

The European Medicines Agency (EMA) announced Friday that an expert panel of the agency endorsed expanding the marketing ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

The U.K. drugmaker GSK is seeking to expand regulatory approval for its new respiratory syncytial virus vaccine to include younger adults, even as other manufacturers’ new RSV products face ...

The European Union health regulator recommended the expanded use of GSK's RSV vaccine in adults aged 50 to 59. The decision ...

GSK recently launched the Arexy vaccine to target RSV. The Advisory Committee on Immunization Practices is now recommending RSV vaccination for all adults above 74 years in age, versus 60 years ...

(RTTNews) - GSK plc (GSK, GSK.L) announced Monday that its Respiratory Syncytial Virus or RSV vaccine, Arexvy, has received positive opinion from the European Medicines Agency's Committee for ...